Development of pluripotent stem cells for vascular therapy

Katharina S. Volz, Erik Miljan, Amanda Khoo, John P. Cooke

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

Peripheral arterial disease (PAD) is characterized by reduced limb blood flow due to arterial obstruction. Current treatment includes surgical or endovascular procedures, the failure of which may result in amputation of the affected limb. An emerging therapeutic approach is cell therapy to enhance angiogenesis and tissue survival. Small clinical trials of adult progenitor cell therapies have generated promising results, although large randomized clinical trials using well-defined cells have not been performed. Intriguing pre-clinical studies have been performed using vascular cells derived from human embryonic stem cells (hESC) or human induced pluripotent stem cells (hiPSCs). In particular, hiPSC-derived vascular cells may be a superior approach for vascular regeneration. The regulatory roadmap to the clinic will be arduous, but achievable with further understanding of the reprogramming and differentiation processes; with meticulous attention to quality control; and perseverance.

Original languageEnglish (US)
Pages (from-to)288-296
Number of pages9
JournalVascular Pharmacology
Volume56
Issue number5-6
DOIs
StatePublished - May 2012

Keywords

  • Angiogenesis
  • Nuclear reprogramming
  • Peripheral arterial disease
  • Regeneration
  • Regenerative medicine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Physiology

Fingerprint Dive into the research topics of 'Development of pluripotent stem cells for vascular therapy'. Together they form a unique fingerprint.

Cite this